(Q44381062)

2 December 2017

0 references

1 reference

title

Lamivudine resistant occult HBV: implications for public health? (English)

1 reference

2 December 2017

0 references

1 reference

Scott Bowden

1

1 reference

2 December 2017

Angeline Bartholomeusz

series ordinal

2

1 reference

2 December 2017

Stephen Locarnini

series ordinal

3

1 reference

2 December 2017

publication date

1 April 2003

1 reference

2 December 2017

published in

Journal of Hepatology

1 reference

2 December 2017

volume

38

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

526-528

1 reference

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Occult hepatitis B virus infection and its clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Occult hepatitis B virus infection: a hidden menace?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Reduced transcription and progeny virus production of hepatitis B virus containing an 8-bp deletion in basic core promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Treatment of chronic hepatitis B: case selection and duration of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Reduced antiretroviral drug susceptibility among patients with primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

Primary infection with a lamivudine-resistant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900079-5

7 January 2021

10.1016/S0168-8278(03)00079-5

Identifiers

DOI

1 reference

2 December 2017

1 reference